LAUSR

Fibrosis, the self-repair process of the body after tissue damage, is a common pathological feature of many chronic inflammatory diseases. It occurs in a variety of organs, leading to structural de-struction and hypofunction, and even organ failure. Fibrosis in organ tissues is characterized by chronic inflammation, excessive accumulation of extracellular matrix (ECM) components, and the decrease of parenchymal cells. Fibrosis is caused by persistent in-fections, toxins, autoimmune diseases, radiation, and mechanical injury. To date, there are various therapeutic strategies for organ fibrosis, such as changing lifestyle, using antiviral drugs, anti-inflammatory treatment, using interferon, and organ transplantation. Currently, there are only two FDA-approved drugs for the treatment of idiopathic pulmonary fibrosis (IPF), i.e